Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients.

Derya Kıvrak SalimTuğba Akın TelliAli Murat TatlıSadettin KılıçkapPerran Fulden Yumuk

Published in: Cancer chemotherapy and pharmacology (2019)

Weekly carboplatin and paclitaxel might be more tolerable and is as effective as 3 weekly carboplatin and weekly paclitaxel schedule in metastatic elderly NSCLC patients.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
ejection fraction
newly diagnosed
small cell lung cancer
chronic kidney disease
prognostic factors
epidermal growth factor receptor
rectal cancer
double blind